MedTrace Logo

Genomic Determinants and Shared Genetic Pathways of Periodontal Disease

NCT03437798 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2024-04-11

No results posted yet for this study

Summary

Despite significant improvement in treating periodontal disease (PD) and the identification of multiple risk factors, little is known about the specific contribution of genetics to PD pathogenesis. Several genomewide association studies (GWAS) of PD have been published, but only one reported locus has reached the threshold for genome-wide significance. Epidemiological studies and biological experiments established associations and suggested common pathogenetic pathways between PD and cardiovascular disease (CVD), diabetes (DM), and osteoporosis. The overall objective is to identify genetic loci for PD as a first step toward a better understanding of PD pathogenesis. In a preliminary study in the Women's Genome Health Study (WGHS), new-onset cases of PD were associated with a family history of myocardial infarction (MI). Further preliminary analyses presented shared phenotypic variation of PD/CVD, PD/DM, or PD/osteoporosis that could be accounted by the whole-genome genetic matrices. Several variants from the GWAS catalog of bone density and family history of MI were found correlated with PD in the WGHS. Based on these findings and the literature, the central hypothesis is that there are common pathogenetic links between PD and these other diseases and that GWAS using the comorbidity case definitions will help identify potential common loci.

Conditions

Interventions

OTHER

Disease status

Women who reported periodontal disease diagnosis/condition

Sponsors & Collaborators

  • Brigham and Women's Hospital

    collaborator OTHER

  • National Institute of Dental and Craniofacial Research (NIDCR)

    collaborator NIH

  • Tufts University

    lead OTHER

Principal Investigators

  • Kathleen Benoit · Tufts University

  • Yau-Hua Yu, DDS, DMSc · Tufts University School of Dental Medicine

Eligibility

Min Age
45 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2022-05-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03437798 on ClinicalTrials.gov